KIF5B/RET fusion
Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer
The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.
The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.